Applied Therapeutics, Inc. (APLT): Price and Financial Metrics


Applied Therapeutics, Inc. (APLT)

Today's Latest Price: $19.87 USD

0.44 (2.26%)

Updated Sep 25 4:00pm

Add APLT to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

APLT Daily Price Range
APLT 52-Week Price Range

APLT Stock Price Chart Technical Analysis Charts

APLT Price/Volume Stats

Current price $19.87 52-week high $57.39
Prev. close $19.43 52-week low $9.67
Day low $19.06 Volume 184,342
Day high $20.48 Avg. volume 226,173
50-day MA $25.23 Dividend yield N/A
200-day MA $35.39 Market Cap 445.78M

Applied Therapeutics, Inc. (APLT) Company Bio

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY

Most Popular Stories View All

• When Does the Next Bull Run Start?

• Is Now a Good Time to Buy Shares of Carnival Corp.?

• 3 Dividend Stocks with EXPLOSIVE Growth

• Is eBay a Buy at $52?

• 4 DOWNGRADED Stocks to AVOID

View All Top Stories

APLT Latest News Stream

Event/Time News Detail
Loading, please wait...
View All APLT News

APLT Latest Social Stream

Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Applied Therapeutics receives Rare Disease, Orphan designations for AT-007

The FDA grants Pediatric Rare Disease and Orphan Designation to Applied Therapeutic's (APLT) +3.7% AT-007 for treatment of PMM2-CDG, a disease caused by deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins.AT-007, a novel CNS penetrant Aldose Reductase inhibitor (recently given the INN scientific name gavorestat) has demonstrated biological activity in...

Seeking Alpha | September 24, 2020

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted AT-007 both Pediatric Rare Disease Designation and Orphan Drug Designation for treatment of PMM2-CDG. PMM2-CDG is a debilitating rare disease caused by deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins. PMM2-CDG causes multiple organ failure and severe disability, resulting in approximately 20% mortality in the first four years of life.   There are currently no drugs approved to treat PMM2-CDG. AT-007, a ...

Yahoo | September 24, 2020

SHAREHOLDER ALERT: Block & Leviton LLP Reminds Investors that it Is Investigating APLT for Possible Securities Laws Violations; Shareholders Should Contact the Firm

BOSTON, MA / ACCESSWIRE / September 22, 2020 / Block & Leviton LLP (www.

Yahoo | September 22, 2020

Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know

In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $24.36, marking a +1.71% move from the previous day.

Yahoo | September 18, 2020

APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Applied Therapeutics Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether Applied Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action.On or around May 13, 2019, Applied Therapeutics conducted its initial public offering (“IPO”), issuing 4 million shares of common stock priced at $10.00 per share. On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the Company's ACTION-Kids study evaluat...

Yahoo | September 1, 2020

Read More 'APLT' Stories Here

APLT Price Returns

1-mo -15.12%
3-mo -44.14%
6-mo -39.22%
1-year 100.20%
3-year N/A
5-year N/A
YTD -27.16%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7351 seconds.